On 3/3/25, Cardiff Oncology Inc (NASDAQ: CRDF) stock suffered a major decline of -10.0%, closing at $3.82. NORMAL trading volume accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -19.7% during the last week.
Current PriceTarget Research Rating
Cardiff Oncology has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Cardiff Oncology has a very low Appreciation Score of 6 but a very high Power Rating of 89, producing the Low Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment